A guided, step-by-step teaching tool. Answer the clinical questions and it assembles the reasoning — target, suitability, route, regimen and specific options with their caveats.
Timing sets the whole risk–benefit. The favourable window is under 60 or within 10 years of menopause. In POI it is replacement, not optional.
A uterus makes progestogen mandatory for endometrial protection. No uterus usually means oestrogen alone — with one exception.
Match the treatment to the dominant problem. Systemic MHT is for bothersome vasomotor symptoms; genitourinary symptoms are often a local decision. Tick all that apply.
These pause systemic MHT until investigated or resolved. If any are present, the stream will not build a hormonal regimen. Tick all that apply.
Most "contraindications" are really reasons to choose the patch, gel or spray rather than to withhold therapy. Tick all that apply.
MHT is not contraception. A perimenopausal woman can still conceive — 2 years after the LMP if under 50, 1 year if over 50.
Shared decision-making matters for adherence. Preference is weighed against the risk profile, not instead of it.